Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 368 of 1,261
  1. US 10906913

    NMDA receptor modulators and uses thereof

    Northwestern University · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  2. US 10906891

    Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

    Vertex Pharmaceuticals Incorporated · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  3. US 10906896

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  4. US 10905784

    Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  5. US 10906864

    Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDS) and methods of treating inflammation related conditions

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  6. US 10905782

    Compositions for enhancing transport of molecules into cells

    Sarepta Therapeutics, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  7. US 10905770

    Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases

    MacRegen, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  8. US 10905775

    Particulate constructs for release of active agents

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  9. US 10906985

    Targeted engineered interferon and uses thereof

    Orionis Biosciences, Inc · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  10. US 10905755

    Vaccines for human papilloma virus and methods for using the same

    Inovio Pharmaceuticals, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  11. US 10905721

    Device and methods for platelet lysis or activation

    Regenexx, LLC · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  12. US 10905736

    Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism

    The Regents of the University of California · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  13. US 10905768

    Heterocyclic degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  14. US 10905709

    Modified antisense oligomers for exon inclusion in spinal muscular atrophy

    Sarepta Therapeutics, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  15. US 10905692

    Combination therapy for treating malignancies

    Agios Pharmaceuticals, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  16. US 10905683

    Compositions and uses of amidine derivatives

    BioCryst Pharmaceuticals, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  17. US 10907170

    Increasing levels of nicotinic alkaloids in plants

    22ND CENTURY LIMITED, LLC · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  18. US 10905690

    Treatment of congenital adrenal hyperplasia

    Neurocrine Biosciences, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  19. US 10905693

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  20. US 10906871

    Processes for making, and methods of using, glycopyrronium compounds

    Dermira, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  21. US 10907154

    Exon skipping compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  22. US 10907158

    Antisense antibacterial compounds and methods

    The Board of Regents of the University of Texas System · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  23. US 10907160

    Methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  24. US 10899793

    Melanocortin ligands and methods of use thereof

    Regents of the University of Minnesota · Granted Jan 26, 2021 · Expires Jan 21, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.